VHLL-BCN
Based on 1 Customer Validation
VHLL-BCN is a ligand targeting the VHL E3 ligase, which can be used for the synthesis of PROTAC molecules. As a key component of the copper-free SPAAC-based rapid synthesis platform for transcription factor PROTACs, VHLL-BCN is applicable to cancer-related research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 95.06%
- CAS 番号: 2874203-49-1
- 分子式: C35H45N5O6S
- 分子量:663.83
-
保管条件:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Anti-Cancer Compound Library
HY-L025
-
Ubiquitination Compound Library
HY-L050
-
E3 Ligase Ligand Library
HY-L128
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Alkyne Compound Library
HY-L258
生物活性
VHLL-BCN undergoes copper-free SPAAC with azide-modified NF-κB-targeting DNA oligomer under physiological conditions to form a TF-PROTAC that reduces p65 protein levels in cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 2874203-49-1
-
性状 Solid
-
分子量 663.83
-
分子式 C35H45N5O6S
-
Color White to off-white
-
SMILES
O=C(N1[C@@H](C[C@H](C1)O)C(NCC2=CC=C(C3=C(C)N=CS3)C=C2)=O)[C@H](C(C)(C)C)NC(CNC(OC[C@@H]4[C@@]5([H])[C@]4([H])CCC#CCC5)=O)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
DMSO : 8.33 mg/mL (12.55 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
[3]. Zhu Z, et al. (GGAA)3-Based TF-PROTACs Enable Targeted Degradation of ETV6 to Inhibit Ewing Sarcoma Growth. J Am Chem Soc. 2025;147(16):13396-13404. [Content Brief]
[4]. Rodrigues DA, et al. Fulfilling multiple roles in PROTAC design: The emerging potential of oligonucleotides. Eur J Med Chem. 2026;307:118688. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5064 mL | 7.5320 mL | 15.0641 mL | 37.6602 mL |
| 5 mM | 0.3013 mL | 1.5064 mL | 3.0128 mL | 7.5320 mL | |
| 10 mM | 0.1506 mL | 0.7532 mL | 1.5064 mL | 3.7660 mL |
VHLL-BCN 関連分類
HY-148880 関連分類
Powered by Bioz